To examine current knowledge on the clinical utility of therapeutic drug monitoring (TDM) in voriconazole therapy, the impact of CYP2C19 genotype on voriconazole plasma concentrations, and the role of CYP2C19 genotyping in voriconazole therapy.
Data Sources
Three literature searches were conducted for original reports on (1) TDM and voriconazole outcomes and (2) voriconazole and CYP2C19 polymorphisms. Searches were conducted through EMBASE, MEDLINE/PubMed, Scopus, and Cochrane Central Register of Controlled Trials from inception to June 2020.
Study Selection and Data Extraction
Randomized controlled trials, cohort studies, and case series with ≥10 patients were included. Only full-text references in English were eligible.
Data Synthesis
A total of 63 studies were reviewed. TDM was recommended because of established concentration and efficacy/toxicity relationships. Voriconazole trough concentrations ≥1.0 mg/L were associated with treatment success; supratherapeutic concentrations were associated with increased neurotoxicity; and hepatotoxicity associations were more prevalent in Asian populations. CYP2C19 polymorphisms significantly affect voriconazole metabolism, but no relationship with efficacy/safety were found. Genotype-guided dosing with TDM was reported to increase chances of achieving therapeutic range.
Relevance to Patient Care and Clinical Practice
Genotype-guided dosing with TDM is a potential solution to optimizing voriconazole efficacy while avoiding treatment failures and common toxicities.
Conclusions
Voriconazole plasma concentrations and TDM are treatment outcome predictors, but research is needed to form a consensus target therapeutic range and dosage adjustment guidelines based on plasma concentrations. CYP2C19 polymorphisms are a predictor of voriconazole concentrations and metabolism, but clinical implications are not established. Large-scale, high-methodological-quality trials are required to investigate the role for prospective genotyping and establish CYP2C19-guided voriconazole dosing recommendations.
ScholzIOberwittlerHRiedelKD, et al. Pharmacokinetics, metabolism and bioavailability of the triazole antifungal agent voriconazole in relation to CYP2C19 genotype. Br J Clin Pharmacol. 2009;68:906-915. doi:10.1111/j.1365-2125.2009.03534.x
3.
RoffeySJColeSCombyP, et al. The disposition of voriconazole in mouse, rat, rabbit, guinea pig, dog, and human. Drug Metab Dispos. 2003;31:731-741. doi:10.1124/dmd.31.6.731
4.
Owusu ObengAEgelundEFAlsultanAPeloquinCAJohnsonJA. CYP2C19 polymorphisms and therapeutic drug monitoring of voriconazole: are we ready for clinical implementation of pharmacogenomics?Pharmacotherapy. 2014;34:703-718. doi:10.1002/phar.1400
5.
CaudleKEDunnenbergerHMFreimuthRR, et al. Standardizing terms for clinical pharmacogenetic test results: consensus terms from the Clinical Pharmacogenetics Implementation Consortium (CPIC). Genet Med. 2017;19:215-223. doi:10.1038/gim.2016.87
6.
LaverdiereMBowEJRotsteinC, et al. Therapeutic drug monitoring for triazoles: a needs assessment review and recommendations from a Canadian perspective. Can J Infect Dis Med Microbiol. 2014;25:327-343. doi:10.1155/2014/340586
7.
LuongMLAl-DabbaghMGrollAH, et al. Utility of voriconazole therapeutic drug monitoring: a meta-analysis. J Antimicrob Chemother. 2016;71:1786-1799. doi:10.1093/jac/dkw099
8.
JinHWangTFalcioneBA, et al. Trough concentration of voriconazole and its relationship with efficacy and safety: a systematic review and meta-analysis. J Antimicrob Chemother. 2016;71:1772-1785. doi:10.1093/jac/dkw045
9.
TheuretzbacherUIhleFDerendorfH. Pharmacokinetic/pharmacodynamic profile of voriconazole. Clin Pharmacokinet. 2006;45:649-663. doi:10.2165/00003088-200645070-00002
10.
PattersonTFThompsonGRIIIDenningDW, et al. Practice guidelines for the diagnosis and management of aspergillosis: 2016 update by the Infectious Diseases Society of America. Clin Infect Dis. 2016;63:e1-e160. doi:10.1093/cid/ciw326
11.
ChauMMKongDCMvan HalSJ, et al. Consensus guidelines for optimising antifungal drug delivery and monitoring to avoid toxicity and improve outcomes in patients with haematological malignancy, 2014. Intern Med J. 2014;44:1364-1388. doi:10.1111/imj.12600
12.
HamadaYTokimatsuIMikamoH, et al. Practice guidelines for therapeutic drug monitoring of voriconazole: a consensus review of the Japanese Society of Chemotherapy and the Japanese Society of Therapeutic Drug Monitoring. J Infect Chemother. 2013;19:381-392. doi:10.1007/s10156-013-0607-8
13.
MorrisseyCOGilroyNMMacesicN, et al. Consensus guidelines for the use of empiric and diagnostic-driven antifungal treatment strategies in haematological malignancy, 2014. Intern Med J. 2014;44:1298-1314. doi:10.1111/imj.12596
14.
AshbeeHRBarnesRAJohnsonEMRichardsonMDGortonRHopeWW. Therapeutic drug monitoring (TDM) of antifungal agents: guidelines from the British Society for Medical Mycology. J Antimicrob Chemother. 2014;69:1162-1176. doi:10.1093/jac/dkt508
15.
PurkinsLWoodNGhahramaniPGreenhalghKAllenMJKleinermansD. Pharmacokinetics and safety of voriconazole following intravenous- to oral-dose escalation regimens. Antimicrob Agents Chemother. 2002;46:2546-2553.
16.
PurkinsLWoodNGreenhalghKEveMDOliverSDNicholsD. The pharmacokinetics and safety of intravenous voriconazole—a novel wide-spectrum antifungal agent. Br J Clin Pharmacol. 2003;56(suppl 1):2-9. doi:10.1046/j.1365-2125.2003.01992.x
17.
Cabral-GaleanoERuiz-CampsILen-AbadO, et al. Clinical usefulness of therapeutic drug monitoring of voriconazole in a university hospital. Enferm Infecc Microbiol Clin. 2015;33:298-302. doi:10.1016/j.eimc.2014.09.005
18.
PascualACalandraTBolaySBuclinTBilleJMarchettiO. Voriconazole therapeutic drug monitoring in patients with invasive mycoses improves efficacy and safety outcomes. Clin Infect Dis. 2008;46:201-211. doi:10.1086/524669
19.
ParkWBKimNHKimKH, et al. The effect of therapeutic drug monitoring on safety and efficacy of voriconazole in invasive fungal infections: a randomized controlled trial. Clin Infect Dis. 2012;55:1080-1087. doi:10.1093/cid/cis599
20.
von EiffMRoosNSchultenRHesseMZühlsdorfMvan de LooJ. Pulmonary aspergillosis: early diagnosis improves survival. Respiration. 1995;62:341-347. doi:10.1159/000196477
21.
GareyKWRegeMPaiMP, et al. Time to initiation of fluconazole therapy impacts mortality in patients with candidemia: a multi-institutional study. Clin Infect Dis. 2006;43:25-31. doi:10.1086/504810
22.
MoherDLiberatiATetzlaffJAltmanDG; PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ. 2009;339:b2535. doi:10.1136/bmj.b2535
23.
HigginsJPTAltmanDGGøtzschePC, et al. The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials. BMJ. 2011;343:d5928. doi:10.1136/bmj.d5928
24.
WellsGSheaBO’ConnellD, et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. Published January 2014. Accessed July 21, 2020. http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp
25.
The Joanna Briggs Institute. Joanna Briggs Institute Reviewers’ Manual: 2014. The Joanna Briggs Institute; 2014.
26.
SmithJSafdarNKnasinskiV, et al. Voriconazole therapeutic drug monitoring. Antimicrob Agents Chemother. 2006;50:1570-1572. doi:10.1128/AAC.50.4.1570-1572.2006
27.
TrifilioSSinghalSWilliamsS, et al. Breakthrough fungal infections after allogeneic hematopoietic stem cell transplantation in patients on prophylactic voriconazole. Bone Marrow Transpl. 2007;40:451-456. doi:10.1038/sj.bmt.1705754
28.
OkudaTOkudaAWatanbeNTakaoMTakayanagiK. Retrospective serological tests for determining the optimal blood concentration of voriconazole for treating fungal infection. Yakugaku Zasshi. 2008;128:1811-1818. doi:10.1248/yakushi.128.1811
29.
UedaKNannyaYKumanoK, et al. Monitoring trough concentration of voriconazole is important to ensure successful antifungal therapy and to avoid hepatic damage in patients with hematological disorders. Int J Hematol. 2009;89:592-599. doi:10.1007/s12185-009-0296-3
30.
BergeMGuillemainRBoussaudV, et al. Voriconazole pharmacokinetic variability in cystic fibrosis lung transplant patients. Transpl Infect Dis. 2009;11:211-219. doi:10.1111/j.1399-3062.2009.00384.x
31.
MiyakisSvan HalSJSolvagCJSRayJMarriottD. Clinician ordering practices for voriconazole therapeutic drug monitoring: experiences of a referral laboratory. Ther Drug Monit. 2010;32:661-664. doi:10.1097/FTD.0b013e3181ea3de6
32.
EidenCCociglioMHillaire-BuysD, et al. Pharmacokinetic variability of voriconazole and N-oxide voriconazole measured as therapeutic drug monitoring. Xenobiotica. 2010;40:701-706. doi:10.3109/00498254.2010.503814
33.
RacilZWinterovaJKoubaM, et al. Monitoring trough voriconazole plasma concentrations in haematological patients: real life multicentre experience. Mycoses. 2012;55:483-492. doi:10.1111/j.1439-0507.2012.02186.x
34.
MitsaniDNguyenMHShieldsRK, et al. Prospective, observational study of voriconazole therapeutic drug monitoring among lung transplant recipients receiving prophylaxis: factors impacting levels of and associations between serum troughs, efficacy, and toxicity. Antimicrob Agents Chemother. 2012;56:2371-2377. doi:10.1128/AAC.05219-11
35.
Gómez-LópezACendejas-BuenoECuestaI, et al. Voriconazole serum levels measured by high-performance liquid chromatography: a monocentric study in treated patients. Med Mycol. 2012;50:439-445. doi:10.3109/13693786.2011.630039
36.
DoltonMJRayJEChenSCANgKPontLGMcLachlanAJ. Multicenter study of voriconazole pharmacokinetics and therapeutic drug monitoring. Antimicrob Agents Chemother. 2012;56:4793-4799. doi:10.1128/AAC.00626-12
37.
ChuHYJainRXieHPottingerPFredricksDN. Voriconazole therapeutic drug monitoring: retrospective cohort study of the relationship to clinical outcomes and adverse events. BMC Infect Dis. 2013;13:105. doi:10.1186/1471-2334-13-105
38.
SuzukiYTokimatsuISatoY, et al. Association of sustained high plasma trough concentration of voriconazole with the incidence of hepatotoxicity. Clin Chim Acta. 2013;424:119-122. doi:10.1016/j.cca.2013.05.025
39.
AouintiIGaiesETrabelsiS, et al. Voriconazole therapeutic drug monitoring. Fundam Clin Pharmacol. 2013;27:67. doi:10.1111/fcp.12026
40.
HoeniglMDuettmannWRaggamRB, et al. Potential factors for inadequate voriconazole plasma concentrations in intensive care unit patients and patients with hematological malignancies. Antimicrob Agents Chemother. 2013;57:3262-3267. doi:10.1128/AAC.00251-13
41.
SainiLSekiJTKumarD, et al. Serum voriconazole level variability in patients with hematological malignancies receiving voriconazole therapy. Can J Infect Dis Med Microbiol. 2014;25:271-276. doi:10.1155/2014/214813
42.
NeofytosDOstranderDShohamS, et al. Voriconazole therapeutic drug monitoring: results of a prematurely discontinued randomized multicenter trial. Transpl Infect Dis. 2015;17:831-837.
43.
YiWMSchoepplerKEJaegerJ, et al. Voriconazole and posaconazole therapeutic drug monitoring: a retrospective study. Ann Clin Microbiol Antimicrob. 2017;16:60. doi:10.1186/s12941-017-0235-8
44.
SebaalyJCMacVaneSHHassigTB. Voriconazole concentration monitoring at an academic medical center. Am J Health Syst Pharm. 2016;73(5, suppl 1):S14-S21. doi:10.2146/ajhp150372
45.
ZoniosDYamazakiHMurayamaN, et al. Voriconazole metabolism, toxicity, and the effect of cytochrome P450 2C19 genotype. J Infect Dis. 2014;209:1941-1948. doi:10.1093/infdis/jiu017
46.
MatsumotoKAbematsuKShigemiA, et al. Therapeutic drug monitoring of voriconazole in Japanese patients: analysis based on clinical practice data. J Chemother. 2016;28:198-202. doi:10.1179/1973947815Y.0000000057
47.
LeeYJLeeSOChoiSH, et al. Initial voriconazole trough blood levels and clinical outcomes of invasive aspergillosis in patients with hematologic malignancies. Med Mycol. 2013;51:324-330. doi:10.3109/13693786.2012.694082
LeeSKimBHNamWS, et al. Effect of CYP2C19 polymorphism on the pharmacokinetics of voriconazole after single and multiple doses in healthy volunteers. J Clin Pharmacol. 2012;52:195-203. doi:10.1177/0091270010395510
50.
WangGLeiHPLiZ, et al. The CYP2C19 ultra-rapid metabolizer genotype influences the pharmacokinetics of voriconazole in healthy male volunteers. Eur J Clin Pharmacol. 2009;65:281-285. doi:10.1007/s00228-008-0574-7
51.
IkedaYUmemuraKKondoKSekiguchiKMiyoshiSNakashimaM. Pharmacokinetics of voriconazole and cytochrome p450 2C19 genetic status. Clin Pharmacol Ther. 2004;75:587-588. doi:10.1016/j.clpt.2004.02.002
52.
WeissJHoevelMMTBurhenneJ, et al. CYP2C19 genotype is a major factor contributing to the highly variable pharmacokinetics of voriconazole. J Clin Pharmacol. 2009;49:196-204. doi:10.1177/0091270008327537
53.
ChawlaPKNandaySRDheraiAJ, et al. Correlation of CYP2C19 genotype with plasma voriconazole levels: a preliminary retrospective study in Indians. Int J Clin Pharm. 2015;37:925-930. doi:10.1007/s11096-015-0143-y
54.
Gautier-VeyretEFonroseXToniniJ, et al. Variability of voriconazole plasma concentrations after allogeneic hematopoietic stem cell transplantation: impact of cytochrome p450 polymorphisms and comedications on initial and subsequent trough levels. Antimicrob Agents Chemother. 2015;59:2305-2314. doi:10.1128/AAC.04838-14
55.
YamadaTMinoYYagiTNaitoTKawakamiJ. Saturated metabolism of voriconazole N-oxidation resulting in nonlinearity of pharmacokinetics of voriconazole at clinical doses. Biol Pharm Bull. 2015;38:1496-1503. doi:10.1248/bpb.b15-00241
56.
LamoureuxFDuflotTWoillardJB, et al. Impact of CYP2C19 genetic polymorphisms on voriconazole dosing and exposure in adult patients with invasive fungal infections. Int J Antimicrob Agents. 2016;47:124-131. doi:10.1016/j.ijantimicag.2015.12.003
57.
ChuwongwattanaSJantararoungtongTChitasombatMN, et al. A prospective observational study of CYP2C19 polymorphisms and voriconazole plasma level in adult Thai patients with invasive aspergillosis. Drug Metab Pharmacokinet. 2016;31:117-122. doi:10.1016/j.dmpk.2015.12.005
58.
LiZWPengFHYanM, et al. Impact of CYP2C19 genotype and liver function on voriconazole pharmacokinetics in renal transplant recipients. Ther Drug Monit. 2017;39:422-428. doi:10.1097/FTD.0000000000000425
59.
YouHDongYZouY, et al. Voriconazole therapeutic drug monitoring: factors associated with supratherapeutic and subtherapeutic voriconazole concentrations. Int J Clin Pharmacol Ther. 2018;56:239-246. doi:10.5414/CP203184
60.
EbrahimpourS. Impact of CYP2C19 polymorphisms on serum concentration of voriconazole in Iranian hematological patients. J Res Pharm Pract. 2018;6:228-232. doi:10.4103/jrpp.JRPP
61.
NiiokaTFujishimaNAbumiyaM, et al. Relationship between the CYP2C19 phenotype using the voriconazole-to-voriconazole N-oxide plasma concentration ratio and demographic and clinical characteristics of Japanese patients with different CYP2C19 genotypes. Ther Drug Monit. 2017;39:514-521. doi:10.1097/FTD.0000000000000441
62.
SibbingDGebhardDKochW, et al. Isolated and interactive impact of common CYP2C19 genetic variants on the antiplatelet effect of chronic clopidogrel therapy. J Thromb Haemost. 2010;8:1685-1693. doi:10.1111/j.1538-7836.2010.03921.x
63.
WangTZhuHSunJ, et al. Efficacy and safety of voriconazole and CYP2C19 polymorphism for optimised dosage regimens in patients with invasive fungal infections. Int J Antimicrob Agents. 2014;44:436-442. doi:10.1016/j.ijantimicag.2014.07.013
64.
MatsumotoKIkawaKAbematsuK, et al. Correlation between voriconazole trough plasma concentration and hepatotoxicity in patients with different CYP2C19 genotypes. Int J Antimicrob Agents. 2009;34:91-94. doi:10.1016/j.ijantimicag.2009.01.008
65.
TrubianoJACroweAWorthLJThurskyKASlavinMA. Putting CYP2C19 genotyping to the test: utility of pharmacogenomic evaluation in a voriconazole-treated haematology cohort. J Antimicrob Chemother. 2015;70:1161-1165. doi:10.1093/jac/dku529
66.
KimSHYimDSChoiSM, et al. Voriconazole-related severe adverse events: clinical application of therapeutic drug monitoring in Korean patients. Int J Infect Dis. 2011;15:e753-e758. doi:10.1016/j.ijid.2011.06.004
67.
BergeMGuillemainRTrégouetDA, et al. Effect of cytochrome P450 2C19 genotype on voriconazole exposure in cystic fibrosis lung transplant patients. Eur J Clin Pharmacol. 2011;67:253-260. doi:10.1007/s00228-010-0914-2
68.
BrüggemannRJMBlijlevensNMABurgerDMFrankeBTrokePFDonnellyJP. Pharmacokinetics and safety of 14 days intravenous voriconazole in allogeneic haematopoietic stem cell transplant recipients. J Antimicrob Chemother. 2010;65:107-113. doi:10.1093/jac/dkp416
69.
LevinMDden HollanderJGvan der HoltB, et al. Hepatotoxicity of oral and intravenous voriconazole in relation to cytochrome P450 polymorphisms. J Antimicrob Chemother. 2007;60:1104-1107. doi:10.1093/jac/dkm330
70.
HashemizadehZBadieePMalekhoseiniSShahrakiHRGeramizadehBMontaserieH. Observational study of associations between voriconazole therapeutic drug monitoring, toxicity, and outcome in liver transplant patients. Clin Ther. 2017;61:1-10.
71.
KimSHLeeDGKwonJC, et al. Clinical impact of cytochrome P450 2C19 genotype on the treatment of invasive aspergillosis under routine therapeutic drug monitoring of voriconazole in a Korean population. Infect Chemother. 2013;45:406-414. doi:10.3947/ic.2013.45.4.406
72.
HicksJKQuilitzREKomrokjiRS, et al. Prospective CYP2C19-guided voriconazole prophylaxis in patients with neutropenic acute myeloid leukemia reduces the incidence of subtherapeutic antifungal plasma concentrations. Clin Pharmacol Ther. 2020;107:563-570. doi:10.1002/cpt.1641
73.
PatelJNHamadehISRobinsonM, et al. Evaluation of CYP2C19 genotype-guided voriconazole prophylaxis after allogeneic hematopoietic cell transplant. Clin Pharmacol Ther. 2020;107:571-579. doi:10.1002/cpt.1642
74.
BrüggemannRJMvan der LindenJWMVerweijPEBurgerDMWarrisA. Impact of therapeutic drug monitoring of voriconazole in a pediatric population. Pediatr Infect Dis J. 2011;30:533-534. doi:10.1097/INF.0b013e318204d227
75.
Soler-PalacínPFrickMAMartín-NaldaA, et al. Voriconazole drug monitoring in the management of invasive fungal infection in immunocompromised children: a prospective study. J Antimicrob Chemother. 2012;67:700-706. doi:10.1093/jac/dkr517
76.
PieperSKolveHGumbingerHGGoletzGWürthweinGGrollAH. Monitoring of voriconazole plasma concentrations in immunocompromised paediatric patients. J Antimicrob Chemother. 2012;67:2717-2724. doi:10.1093/jac/dks258
77.
ChoiSHLeeSYHwangJY, et al. Importance of voriconazole therapeutic drug monitoring in pediatric cancer patients with invasive aspergillosis. Pediatr Blood Cancer. 2013;60:82-87. doi:10.1002/pbc.24262
78.
BartelinkIHWolfsTJonkerM, et al. Highly variable plasma concentrations of voriconazole in pediatric hematopoietic stem cell transplantation patients. Antimicrob Agents Chemother. 2013;57:235-240. doi:10.1128/AAC.01540-12
79.
TuckerLHigginsTEgelundEFZouBVijayanVPeloquinCA. Voriconazole monitoring in children with invasive fungal infections. J Pediatr Pharmacol Ther. 2015;20:17-23. doi:10.5863/1551-6776-20.1.17
80.
KatoKNagaoMYamamotoM, et al. Oral administration and younger age decrease plasma concentrations of voriconazole in pediatric patients. J Infect Chemother. 2015;22:27-31. doi:10.1016/j.jiac.2015.09.008
81.
KangHMLeeHJChoEY, et al. The clinical significance of voriconazole therapeutic drug monitoring in children with invasive fungal infections. Pediatr Hematol Oncol. 2015;32:557-567. doi:10.3109/08880018.2015.1088905
82.
HuLDaiT-TZouLLiT-MDingX-SYinT. Therapeutic drug monitoring of voriconazole in children from a tertiary care center in China. Antimicrob Agents Chemother. 2018;62:e00955-18. doi:10.1128/AAC.00955-18
83.
BoastACurtisNCranswickNGweeA. Voriconazole dosing and therapeutic drug monitoring in children: experience from a paediatric tertiary care centre. J Antimicrob Chemother. 2016;71:2031-2036. doi:10.1093/jac/dkw056
84.
HicksJKCrewsKRFlynnP, et al. Voriconazole plasma concentrations in immunocompromised pediatric patients vary by CYP2C19 diplotypes. Pharmacogenomics. 2014;15:1065-1078. doi:10.2217/pgs.14.53
85.
NaritaAMuramatsuHSakaguchiH, et al. Correlation of CYP2C19 phenotype with voriconazole plasma concentration in children. J Pediatr Hematol Oncol. 2013;35:e219-e223. doi:10.1097/MPH.0b013e3182880eaa
86.
TeusinkAVinksAZhangK, et al. Genotype-directed dosing leads to optimized voriconazole levels in pediatric patients receiving hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2016;22:482-486. doi:10.1016/j.bbmt.2015.11.011
87.
ParkSJSongISKangSW, et al. Pharmacokinetic effect of voriconazole on cyclosporine in the treatment of aspergillosis after renal transplantation. Clin Nephrol. 2012;78:412-418. doi:10.5414/CN107029
88.
ChenKZhangXKeXDuGYangKZhaiS. Individualized medication of voriconazole: a practice guideline of the Division of Therapeutic Drug Monitoring, Chinese Pharmacological Society. Ther Drug Monit. 2018;40:663-674. doi:10.1097/FTD.0000000000000561
89.
ZhongXTongXJuYDuXLiY. Interpersonal factors in the pharmacokinetics and pharmacodynamics of voriconazole: are CYP2C19 genotypes enough for us to make a clinical decision?Curr Drug Metab. 2018;19:1152-1158. doi:10.2174/1389200219666171227200547
90.
MoussetSBuchheidtDHeinzW, et al. Treatment of invasive fungal infections in cancer patients—updated recommendations of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO). Ann Hematol. 2014;93:13-32. doi:10.1007/s00277-013-1867-1
91.
HusainSCamargoJF. Invasive aspergillosis in solid-organ transplant recipients: guidelines from the American Society of Transplantation Infectious Diseases Community of Practice. Clin Transpl. 2019;33:e13544. doi:10.1111/ctr.13544
92.
HicksJKSangkuhlKSwenJJ, et al. Clinical pharmacogenetics implementation consortium guideline (CPIC) for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants: 2016 update. Clin Pharmacol Ther. 2017;102:37-44. doi:10.1002/cpt.597
93.
MoriyamaBKadriSHenningSADannerRLWalshTJPenzakSR. Therapeutic drug monitoring and genotypic screening in the clinical use of voriconazole. Curr Fungal Infect Rep. 2015;9:74-87. doi:10.1007/s12281-015-0219-0
94.
BankPCDCaudleKESwenJJ, et al. Comparison of the guidelines of the Clinical Pharmacogenetics Implementation Consortium and the Dutch Pharmacogenetics Working Group. Clin Pharmacol Ther. 2018;103:599-618. doi:10.1002/cpt.762
95.
RobertsJDWellsGALe MayMR, et al. Point-of-care genetic testing for personalisation of antiplatelet treatment (RAPID GENE): a prospective, randomised, proof-of-concept trial. Lancet. 2012;379:1705-1711. doi:10.1016/S0140-6736(12)60161-5
96.
StimpfleFKarathanosADroppaM, et al. Impact of point-of-care testing for CYP2C19 on platelet inhibition in patients with acute coronary syndrome and early dual antiplatelet therapy in the emergency setting. Thromb Res. 2014;134:105-110. doi:10.1016/j.thromres.2014.05.006
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
